BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166)
China
· Delayed Price · Currency is CNY 30.20
+0.54 (1.82%)
Jan 6, 2025, 4:00 PM CST
BrightGene Bio-Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Operating Revenue | 1,223 | 1,161 | 1,013 | 1,050 | 783.71 | 503.08 | Upgrade
|
| Other Revenue | 18.34 | 18.34 | 4.04 | 2.25 | 1.67 | 0.07 | Upgrade
|
| Revenue | 1,241 | 1,180 | 1,017 | 1,052 | 785.38 | 503.16 | Upgrade
|
| Revenue Growth (YoY) | 7.03% | 15.94% | -3.33% | 34.00% | 56.09% | 23.47% | Upgrade
|
| Cost of Revenue | 571.33 | 542.9 | 390.95 | 470.07 | 363.39 | 187.29 | Upgrade
|
| Gross Profit | 670.14 | 636.61 | 626.38 | 582.34 | 421.99 | 315.87 | Upgrade
|
| Selling, General & Admin | 193.22 | 180.46 | 184.98 | 145.56 | 99.04 | 79.93 | Upgrade
|
| Research & Development | 297.16 | 248.59 | 207.02 | 173.29 | 138.26 | 120.9 | Upgrade
|
| Other Operating Expenses | -0.12 | -1.59 | 5.22 | 4.22 | 2.4 | 3.12 | Upgrade
|
| Operating Expenses | 491.53 | 428.37 | 395 | 333.18 | 238.89 | 207.92 | Upgrade
|
| Operating Income | 178.61 | 208.24 | 231.38 | 249.16 | 183.11 | 107.95 | Upgrade
|
| Interest Expense | -50.44 | -44.42 | -23.71 | -9.7 | -2.04 | -0.23 | Upgrade
|
| Interest & Investment Income | 16.38 | 17.99 | 6.2 | 10.14 | 13.01 | 4.93 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.6 | 2.6 | 12.99 | 4.63 | -11.02 | 1.78 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.27 | -1.88 | -2.17 | -1.77 | -0.92 | -0.48 | Upgrade
|
| EBT Excluding Unusual Items | 147.42 | 182.54 | 224.68 | 252.46 | 182.13 | 113.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | -15.9 | -15.26 | -3.39 | 0.79 | 0.04 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.25 | -0.25 | -0.01 | -0.26 | -0.27 | -1.3 | Upgrade
|
| Other Unusual Items | 27.89 | 21.74 | 20.93 | 4.47 | 9.42 | 7.28 | Upgrade
|
| Pretax Income | 159.16 | 188.77 | 242.21 | 257.46 | 191.32 | 119.94 | Upgrade
|
| Income Tax Expense | 15.72 | 15.35 | 30.78 | 19.9 | 21.96 | 8.86 | Upgrade
|
| Earnings From Continuing Operations | 143.44 | 173.42 | 211.43 | 237.56 | 169.36 | 111.08 | Upgrade
|
| Minority Interest in Earnings | 44.64 | 29.04 | 28.2 | 6.39 | 0.52 | - | Upgrade
|
| Net Income | 188.08 | 202.47 | 239.62 | 243.95 | 169.88 | 111.08 | Upgrade
|
| Net Income to Common | 188.08 | 202.47 | 239.62 | 243.95 | 169.88 | 111.08 | Upgrade
|
| Net Income Growth | -19.55% | -15.51% | -1.77% | 43.60% | 52.93% | 51.75% | Upgrade
|
| Shares Outstanding (Basic) | 419 | 422 | 413 | 407 | 414 | 370 | Upgrade
|
| Shares Outstanding (Diluted) | 419 | 422 | 413 | 407 | 414 | 370 | Upgrade
|
| Shares Change (YoY) | -1.19% | 2.10% | 1.61% | -1.87% | 11.90% | 6.22% | Upgrade
|
| EPS (Basic) | 0.45 | 0.48 | 0.58 | 0.60 | 0.41 | 0.30 | Upgrade
|
| EPS (Diluted) | 0.45 | 0.48 | 0.58 | 0.60 | 0.41 | 0.30 | Upgrade
|
| EPS Growth | -18.58% | -17.24% | -3.33% | 46.34% | 36.67% | 42.86% | Upgrade
|
| Free Cash Flow | -138.97 | -209 | -415.47 | -733.59 | -199.84 | -28.21 | Upgrade
|
| Free Cash Flow Per Share | -0.33 | -0.50 | -1.01 | -1.80 | -0.48 | -0.08 | Upgrade
|
| Dividend Per Share | 0.096 | 0.096 | 0.114 | 0.120 | 0.084 | 0.082 | Upgrade
|
| Dividend Growth | -15.79% | -15.79% | -5.00% | 42.86% | 2.44% | - | Upgrade
|
| Gross Margin | 53.98% | 53.97% | 61.57% | 55.33% | 53.73% | 62.78% | Upgrade
|
| Operating Margin | 14.39% | 17.65% | 22.74% | 23.68% | 23.31% | 21.45% | Upgrade
|
| Profit Margin | 15.15% | 17.17% | 23.55% | 23.18% | 21.63% | 22.08% | Upgrade
|
| Free Cash Flow Margin | -11.19% | -17.72% | -40.84% | -69.71% | -25.44% | -5.61% | Upgrade
|
| EBITDA | 264.6 | 274.37 | 271.03 | 283.34 | 213.31 | 134.11 | Upgrade
|
| EBITDA Margin | 21.31% | 23.26% | 26.64% | 26.92% | 27.16% | 26.65% | Upgrade
|
| D&A For EBITDA | 85.99 | 66.13 | 39.65 | 34.18 | 30.2 | 26.16 | Upgrade
|
| EBIT | 178.61 | 208.24 | 231.38 | 249.16 | 183.11 | 107.95 | Upgrade
|
| EBIT Margin | 14.39% | 17.65% | 22.74% | 23.68% | 23.31% | 21.45% | Upgrade
|
| Effective Tax Rate | 9.88% | 8.13% | 12.71% | 7.73% | 11.48% | 7.39% | Upgrade
|
| Revenue as Reported | 1,241 | 1,180 | 1,017 | 1,052 | 785.38 | 503.16 | Upgrade
|
| Advertising Expenses | - | 0.99 | 0.52 | 1.01 | 1.32 | 1.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.